Somewhat Favorable Media Coverage Somewhat Unlikely to Impact TESARO (TSRO) Share Price

Headlines about TESARO (NASDAQ:TSRO) have trended somewhat positive recently, Accern reports. The research group identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. TESARO earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 44.750624720876 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

These are some of the media stories that may have impacted Accern’s scoring:

Shares of TESARO (NASDAQ:TSRO) traded down $1.79 during midday trading on Friday, hitting $69.23. The company had a trading volume of 1,010,784 shares, compared to its average volume of 1,210,000. The company has a market cap of $3,670.00, a P/E ratio of -8.21 and a beta of 1.51. TESARO has a 1-year low of $59.77 and a 1-year high of $192.94. The company has a current ratio of 4.73, a quick ratio of 4.35 and a debt-to-equity ratio of 0.34.

TESARO (NASDAQ:TSRO) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.69. The business had revenue of $142.77 million for the quarter, compared to the consensus estimate of $130.57 million. TESARO had a negative return on equity of 93.39% and a negative net margin of 251.22%. The business’s revenue was up 740.3% on a year-over-year basis. During the same quarter last year, the business posted ($1.72) EPS. equities research analysts forecast that TESARO will post -8.2 earnings per share for the current year.

Several research analysts have recently commented on the company. BidaskClub upgraded TESARO from a “strong sell” rating to a “sell” rating in a research report on Tuesday. Robert W. Baird reiterated a “neutral” rating and issued a $125.00 target price on shares of TESARO in a research report on Monday, October 2nd. Piper Jaffray Companies reiterated a “hold” rating and issued a $65.00 target price on shares of TESARO in a research report on Thursday, January 18th. Jefferies Group reiterated a “hold” rating and issued a $124.00 target price on shares of TESARO in a research report on Friday, November 3rd. Finally, Credit Suisse Group reiterated an “outperform” rating and issued a $150.00 target price (down previously from $190.00) on shares of TESARO in a research report on Thursday, January 18th. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. TESARO has a consensus rating of “Hold” and a consensus target price of $149.97.

In related news, SVP Martin H. Jr. Huber sold 829 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $85.24, for a total value of $70,663.96. Following the sale, the senior vice president now owns 8,101 shares of the company’s stock, valued at approximately $690,529.24. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 40.50% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact TESARO (TSRO) Share Price” was reported by BBNS and is the property of of BBNS. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://baseballnewssource.com/markets/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-tesaro-tsro-share-price/1871615.html.

About TESARO

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Insider Buying and Selling by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Giants Will Retire No. 25 of Barry Bonds in August
Giants Will Retire No. 25 of Barry Bonds in August
Mookie Betts Awarded Arbitration of $10.5 Million
Mookie Betts Awarded Arbitration of $10.5 Million


Leave a Reply

 
© 2006-2018 BBNS.